Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)

Trial Profile

Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lurbinectedin (Primary) ; Cyclophosphamide; Doxorubicin; Topotecan; Vincristine
  • Indications Small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ATLANTIS
  • Sponsors PharmaMar
  • Most Recent Events

    • 01 Feb 2024 Results of post-hoc analysis of two studies NCT02454972 and NCT02566993, published in the Lung Cancer.
    • 24 Oct 2023 Results assessing the occurrence of chemotherapy-induced myelosuppression events with standard of care chemotherapies for relapsed SCLC and supportive care interventions from NCT02454972, NCT02514447 and NCT02566993, presented at the 48th European Society for Medical Oncology Congress.
    • 08 Sep 2023 According to a PharmaMar media release, result data from this study will be presented at The International Association for the Study of Lung Cancer (IASLC) held in Singapore from September 9th to 12th.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top